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 While there is a broad consensus that coronary artery disease (CAD) contributes to the development of 
HF with reduced ejection fraction (HFrEF), its causal role in HF with preserved ejection fraction (HFpEF) 
is less clear. Conventional observational studies reporting the link between CAD and HFpEF are limited 
by confounding. Use of genetic risk scores (GRS) comprising genetic variants robustly associated with a 
particular phenotype from genome-wide association studies (GWAS) can largely overcome confounding 
through independent causal association of the GRS with the clinical outcome using Mendelian 
randomisation. A recent study from the Framingham cohort suggested that a CAD GRS of 58 genetic 
variants was associated with HFrEF, but not HFpEF, however this study was underpowered to draw 
definitive conclusions and did not account for competing risks.1 The aim of our study was to investigate 
further the differential association of CAD with incident HFrEF and HFpEF in a large, adequately 
powered population study and meta-analysis. 
We conducted a longitudinal analysis of the Genetics of Diabetes Audit and Research Tayside Scotland 
(GoDARTS) study.2 All patients provided informed consent and the study was approved by the East of 
Scotland Research and Ethics Committee. The primary outcome was time to development of HFrEF or 
HFpEF. HF mortality and hospitalisation were obtained from electronic health records including any 
clinically-requested echocardiograms.3 HFrEF was classified as HF mortality or hospitalisation with 
LVEF <50%, while HFpEF was classed as HF with LVEF ≥50%. The CAD GRS was constructed based 
on 64 variants significantly associated with CAD in a 2015 GWAS.4 Weighting was applied to the SNPs 
according to the beta estimates reported in the study and an additive risk score was calculated for each 
patient based on the number of risk alleles and their weighting. Both observational CAD (history of MI 
prior to study entry) and genetically-determined CAD (CAD GRS) were analysed for association with 
incident HFrEF and HFpEF with death and the other HF phenotype treated as competing risks using the 
Fine-Gray method. Hazard ratios for development of HF were calculated with adjustment for age, gender, 
smoking, diabetes, systolic blood pressure, total cholesterol and HDL cholesterol. Finally, fixed-effects 
meta-analysis was performed combining our results with those of Andersson et al.1 A key issue of 
 Mendelian randomization studies is ensuring adequate statistical power. A post-hoc power calculation 
was performed using the methods described by Burgess et al.5 Our meta-analysis had 99.9% power to 
detect an association between CAD GRS and HFrEF and 91.7% power for the detection of a significant 
association between the CAD GRS and HFpEF. A p value <0.05 was considered significant. Statistical 
analyses were performed using R version 3.4.3 and RevMan version 5.3. 
12,919 individuals with available genetic data were included in this study (mean age 63±12 years; 54.3% 
male). 64.5% had diabetes, 8.9% prior myocardial infarction (MI) or unstable angina and 2.7% prior 
history of HF. There were 1,293 HF events, including 752 HFrEF and 442 HFpEF events. 99 HF events 
were unclassified (no echocardiography available).  
Of the 1,152 patients with prior MI, 220 patients developed HFrEF while 95 patients developed HFpEF. 
Prior MI was significantly associated with both HF phenotypes (HFrEF: HR 2.84; 95% CI 2.39-3.37; 
HFpEF: HR 2.25: 95% CI 1.78-2.84; all p<0.00001). Conversely, the CAD GRS was only significantly 
associated with HFrEF (fully adjusted HR 1.33 per 1-unit increase in GRS; 95% CI 1.09-1.62, p=0.001) 
but not HFpEF (fully adjusted HR 1.07 per 1-unit increase in GRS; 95% CI 0.83-1.37, p=0.46) (Figure 
Panel A). Our meta-analysis included 17,309 individuals, with 964 HFrEF events and 638 HFpEF events. 
After adjustment the CAD GRS was significantly associated with HFrEF (HR 1.43 per 1-unit increase in 
GRS; 95% CI 1.20-1.69, p<0.0001). Conversely the CAD GRS was not associated with HFpEF (fully 
adjusted HR 1.06 per 1-unit increase in GRS; 95% CI 0.86-1.30, p=0.52) (Figure Panel B).  
Our key finding is that while there is an observational association of CAD with both HFpEF and HFrEF, 
using Mendelian randomization we found that genetically-determined risk of CAD is significantly 
associated with HFrEF but not HFpEF. We have combined our study with a previous study1 in a meta-
analysis to provide further confidence for this finding. Overall this analysis strongly supports the 
conclusion that CAD may not be causal in HFpEF and its high prevalence in patients with HFpEF is 
likely to be through other commonly associated risk factors. 
 Our study has some limitations. We used a pragmatic approach to classify patients with HFpEF, and did 
not have measures such as natriuretic peptides and left atrial size. Secondly, although we had adequate 
power to determine an effect of the CAD GRS on development of HFpEF, it is possible that a larger 
population might detect a smaller but significant effect, although the clinical importance of this would be 
unclear. 
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 FIGURE LEGEND 
Association of Coronary Artery Disease with Risk of Heart Failure with Reduced versus Preserved 
Ejection Fraction.  
A. Adjusted Hazard Ratios for Observational (red) and Genetic (blue) CAD Risk for Incidence of 
HF. 
Comparison of fully adjusted hazard ratios for observational and genetic CAD risk for risk of HF. 
Dotted line represents hazard ratio = 1. Hazard Ratios adjusted for age, gender, smoking, 
diabetes, systolic blood pressure, total cholesterol and HDL cholesterol. 
B. Meta-analysis of CAD GRS for risk of HF. 
Fixed-effects meta-analysis of studies by Andersson et al.1 and the current study for association 
of CAD GRS with HFrEF and HFpEF. 
  
  
